Skip to main content

Table 1 Main clinical and hematological characteristics of patients at diagnosis (n =75)

From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

Variable Median (range) N (%) (n = 75)
Age, years 66 (32–83)  
 < 65   34
 ≥ 65   41
Gender   
 Male   52 (69)
 Female   23 (31)
Hemoglobin level, g/L 91 (57–136)  
 < 100   50
 ≥ 100   25
Leukocyte count, × 109/L 2.9 (0.8–108)  
 < 4   47
 > 4 and < 11   14
 ≥ 11   14
Platelet count, × 109/L 68 (5–536)  
 < 100   48
 ≥ 100   27
Neutrophil count, × 109/L 1.23 (0.09–13.55)  
 < 0.8   27
 ≥ 0.8   47
 No data   1
Blasts in PB, % 0 (0–74)  
 < 5   55
 ≥ 5   20
Blasts in BM, % 15 (0–92)  
 < 20   49
 ≥ 20   26
Cytogenetic   
 Normal karyotype   28
 Abnormal karyotype   45
 Uninformative CC   2
Cytogenetic category (IPSS-R)   
 Very good   1
 Good   30
 Intermediate   20
 Poor   6
 Very poor   16
 Uninformative CC   2
IPSS risk group (only MDS patients: 49)   
 Intermediate-1   6
 Intermediate-2   23
 High   19
 No data   1
IPSS-R risk group (only MDS patients: 49)   
 Low   1
 Intermediate   9
 High   16
 Very high   21
 No data   2
Treatment   
 AZA 38  
 Other treatment (ICE plus AZA and/or ASCT) 37  
  1. PB peripheral blood, BM bone marrow, Uninformative CC cases with no metaphases, IPSS International Prognostic Score System, IPSS-R Revised IPSS, WHO World Health Organization, AZA azacitidine, ICE idarubicin, cytarabine and etoposide, ASCT allogeneic stem cell transplantation
\